Healthcare [ 12/13 ] | Drug Manufacturers - Specialty & Generic [ 84/164 ]
NASDAQ | Common Stock
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003.
Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | 1.45 Increased by +384.31% | 0.73 Increased by +98.63% |
| Feb 22, 24 | 0.82 Increased by +490.48% | 0.66 Increased by +24.24% |
| Nov 7, 23 | 0.53 Increased by +5.20 K% | 0.52 Increased by +1.92% |
| Aug 3, 23 | 0.34 Increased by +6.25% | 0.29 Increased by +17.24% |
| May 4, 23 | -0.51 Decreased by -215.91% | 0.31 Decreased by -264.52% |
| Feb 23, 23 | -0.21 Increased by +58.82% | -0.14 Decreased by -50.00% |
| Nov 3, 22 | 0.01 Decreased by -95.45% | -0.13 Increased by +107.69% |
| Aug 4, 22 | 0.32 Increased by +18.52% | 1.42 Decreased by -77.46% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 144.92 M Increased by +0.11% | 27.71 M Increased by +259.03% | Increased by +19.12% Increased by +258.86% |
| Dec 31, 23 | 149.75 M Increased by +15.53% | 31.94 M Increased by +543.67% | Increased by +21.33% Increased by +484.05% |
| Sep 30, 23 | 136.71 M Increased by +7.63% | 20.63 M Increased by +4.42 K% | Increased by +15.09% Increased by +4.09 K% |
| Jun 30, 23 | 135.55 M Increased by +9.71% | 13.01 M Increased by +350.57% | Increased by +9.60% Increased by +328.39% |
| Mar 31, 23 | 144.77 M Increased by +72.85% | -17.43 M Decreased by -33.34% | Decreased by -12.04% Increased by +22.86% |
| Dec 31, 22 | 129.62 M Increased by +373.72% | -7.20 M Increased by +71.24% | Decreased by -5.55% Increased by +93.93% |
| Sep 30, 22 | 127.01 M Increased by +61.10% | 457.00 K Decreased by -94.32% | Increased by +0.36% Decreased by -96.47% |
| Jun 30, 22 | 123.55 M Increased by +48.96% | -5.19 M Decreased by -107.13% | Decreased by -4.20% Decreased by -104.78% |